Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single-arm study

Zhenyu Pan, Guozi Yang, Hua He, Gang Zhao, Tingting Yuan, Yu Li, Weiyan Shi, Pengxiang Gao, Lihua Dong, Yunqian Li, Zhenyu Pan, Guozi Yang, Hua He, Gang Zhao, Tingting Yuan, Yu Li, Weiyan Shi, Pengxiang Gao, Lihua Dong, Yunqian Li

Abstract

The prognosis of leptomeningeal metastasis (LM) from solid tumors is extremely poor, especially for patients with adverse prognostic factors. In this phase II clinical trial, we evaluated the efficacy and safety of intrathecal chemotherapy (IC) combined with concomitant involved-field radiotherapy (IF-RT) for treating LM from solid tumors with adverse prognostic factors. Fifty-nine patients with LM from various solid tumors were enrolled between May 2010 and December 2014. Concurrent therapy consisted of concomitant IC (methotrexate 12.5-15 mg and dexamethasone 5 mg, weekly) and IF-RT (whole brain and/or spinal canal RT, 40 Gy/20f). For patients with low Karnofsky performance status (KPS) score and radiotherapy intolerance, induction IC (1-3 times) was given before concurrent therapy. Thirty-eight patients (64.4%) received subsequent treatments. All patients were followed up at least 6 months after LM diagnosis or until death. Primary endpoint evaluated was clinical response rate. Secondary endpoints were overall survival (OS) and safety. The pathological types included lung cancer (n = 42), breast cancer (n = 11) and others (n = 6). Median KPS score was 40 (range 20-70). Fifty-one patients (86.4%) completed concurrent therapy. The overall response rate was 86.4% (51/59). OS ranged from 0.4 to 36.7 months (median 6.5 months), and 1-year-survival rate was 21.3%. Treatment-related adverse events mainly included acute meningitis, chronic-delayed encephalopathy, radiculitis, myelosuppression and mucositis. Twelve patients (20.3%) had grade III-V toxic reactions. We concluded that IC combined with concomitant IF-RT, with significant efficacy and acceptable toxicity, may be an optimal therapeutic option for treatment of LM from solid tumors with adverse prognostic factors. LM, in which cancer cells spread to membranes enveloping the brain and spinal cord, is a devastating complication of solid cancers. Existing LM therapies center on IC. In this prospective clinical study, the authors combined intrathecal methotrexate with involved-field radiotherapy in a concomitant regimen, showing that the approach can potentially improve quality of life for patients with adverse prognostic factors. Concurrent radiotherapy-bolstered IC by contributing to prolonged remission of neurological symptoms and increasing OS. The findings suggest that the concomitant regimen could be an optimal treatment option for LM.

Keywords: central nervous system; intrathecal chemotherapy; leptomeningeal metastasis; metastasis; radiation therapy; solid tumor.

© 2016 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Figures

Figure 1
Figure 1
Protocol schema. IC: intrathecal chemotherapy; RT: radiation therapy; KPS: Karnofsky performance status; MTX: methotrexate; DXM: dexamethasone.

References

    1. Le Rhun E, Taillibert S, Chamberlain MC. Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg Neurol Int 2013; 4:S265
    1. Chamberlain MC. Combined‐modality treatment of leptomeningeal gliomatosis. Neurosurgery 2003; 52:324–30.
    1. Chamberlain MC, Tsao‐Wei D, Groshen S. Neoplastic meningitis‐related encephalopathy prognostic significance. Neurology 2004; 63:2159–61.
    1. Chamberlain MC, Glantz M, Groves MD, et al. Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment. Semin Oncol 2009; 36:S35–45.
    1. Taillibert S, Laigle‐Donadey F, Chodkiewicz C, et al. Leptomeningeal metastases from solid malignancy: a review. J Neurooncol 2005; 75:85–99.
    1. Chamberlain MC, Johnston SK, Glantz MJ. Neoplastic meningitis‐related prognostic significance of the Karnofsky performance status. Arch Neurol 2009; 66:74–8.
    1. Brem SS, Bierman PJ, Black P, et al. Central nervous system cancers: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2005; 3:644–90.
    1. Chamberlain MC, Kormanik PA. Prognostic significance of 111indium‐DTPA CSF flow studies in leptomeningeal metastases. Neurology 1996; 46:1674–7.
    1. Chamberlain MC, Kormanik PA. Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch Neurol 1997; 54:1364–8.
    1. Chamberlain M. Leptomeningeal metastases: a review of evaluation and treatment. J Neuro oncol 1998; 37:271–84.
    1. Gani C, Müller A‐C, Eckert F, et al. Outcome after whole brain radiotherapy alone in intracranial leptomeningeal carcinomatosis from solid tumors. Strahlenther Onkol 2012; 188:148–53.
    1. Morris PG, Reiner AS, Szenberg OR, et al. Leptomeningeal metastasis from non‐small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 2012; 7:382–5.
    1. Clarke JL, Perez HR, Jacks LM, et al. Leptomeningeal metastases in the MRI era. Neurology 2010; 74:1449–54.
    1. Chamberlain M, Soffietti R, Raizer J, et al. Leptomeningeal metastasis: a response assessment in neuro‐oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro‐Oncology 2014; 16:1176–85.
    1. Glantz MJ, LaFollette S, Jaeckle K, et al. Randomized trial of a slow‐ release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999; 17:3110–6.
    1. Cole BF1, Glantz MJ, Jaeckle KA, et al. Quality‐of‐life‐adjusted survival comparison of sustained‐release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer 2003; 97:3053–60.
    1. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained‐release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999; 5:3394–402.
    1. Groves MD. Leptomeningeal metastasis: still a challenge. ASCO Educational Book; 2008. 80–87.
    1. Chamberlain MC. Neoplastic meningitis. J Clin Oncol 2005; 23:3605–13.
    1. Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 1975; 195:73–83.
    1. Chamberlain MC, Kormanik P, Jaeckle KA, et al. 111Indium‐diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 1999; 52:214.
    1. Novak LJ. Radiotherapy of the central nervous system in acute leukemia. Hematol Oncol 1989; 11:87–104.
    1. Bleyer WA. Current status of intrathecal chemotherapy for human meningeal neoplasms. Natl Cancer Inst Monogr 1977; 46:171–8.
    1. Hitchins RN, Bell DR, Woods RL, et al. A prospective randomized trial of single‐agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987; 5:1655–62.
    1. Chamberlain MC, SK J. Neoplastic meningitis: survival as a function of cerebrospinal fluid cytology. Cancer 2009; 115:1941–6.
    1. Vedrine L, Artru P, Tournigand C, et al. Meningeal carcinomatosis in gastric cancer. Gastroenterol Clin Biol 2001; 25:422–4.
    1. Kim A, Lee J‐E, Jang W‐S, et al. A combination of methotrexate and irradiation promotes cell death in NK/T‐cell lymphoma cells via down‐regulation of NF‐κB signaling. Leuk Res 2012; 36:350–57.
    1. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982; 49:759–72.
    1. Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 1993; 11:561–9.
    1. Shapiro WR, Schmid M, Glantz M, et al. A randomized phase III/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis. J Clin Oncol 2006; 24:1528s
    1. Groves MD, Glantz MJ, Chamberlain MC, et al. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro‐Oncology 2008; 10:208–15.
    1. Chamberlain MC, Wei‐Tao DD, Groshen S. A phase 2 trial of intra‐CSF etoposide in the treatment of neoplastic meningitis. Cancer 2006; 106:2021–7.
    1. Scott BJ, Oberheim‐Bush NA, Kesari S. Leptomeningeal metastasis in breast cancer—a systematic review. Oncotarget 2016; 7: 3740–47.
    1. Sause WT, Crowley J, Eyre HJ, et al. Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumor leptomeningeal metastases—a southwest oncology group study. J Neurooncol 1988; 6:107–12.
    1. Bussani R, Cova M, Pozzi‐Mucelli R, et al. Extensive metastatic leptomeningeal melanomatosis as the first clinical sign of a cutaneous melanoma: morphological correlations between magnetic resonance imaging and autopsy findings. A case report. Hum Pathol 2003; 34:625–8.
    1. Jackman DM, Cioffredi LA, Jacobs L, et al. A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non‐small cell lung cancer. Oncotarget 2015; 6:4527–36.
    1. Scott BJ, van Vugt VA, Rush T, et al. Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. J Neurooncol 2014; 119:361–8.
    1. Boogerd W, van den Bent MJ, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomized study. Eur J Cancer 2004; 40:2726–33.
    1. Chamberlain MC, Kormanik P. Carcinoma meningitis secondary to non‐small cell lung cancer: combined modality therapy. Arch Neurol 1998; 55:506–12.
    1. Park JH, Kim YJ, Lee J‐O, et al. Clinical outcomes of leptomeningeal metastasis in patients with non‐small cell lung cancer in the modern chemotherapy era. Lung Cancer 2012; 76:387–92.
    1. Boogerd W, Hart AAM, van der Sande JJ, et al. Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 1991; 67:1685–95.
    1. Fizazi K, Asselain B, Vincent‐Salomon A, et al. Meningeal carcinomatosis in patients with breast carcinoma: clinical features, prognostic factors, and results of a high‐dose intrathecal methotrexate regimen. Cancer 1996; 77:1315–23.
    1. Grant R, Naylor B, Greenberg HS, et al. Clinical outcome in aggressively treated meningeal carcinomatosis. Arch Neurol 1994; 51:457–61.
    1. Siegal T, Lossos A, Pfeffer MR. Leptomeningeal metastases analysis of 31 patients with sustained off‐therapy response following combined‐modality therapy. Neurology 1994; 44:1463–3.
    1. Kerr JZ, Berg S, Blaney SM. Intrathecal chemotherapy. Crit Rev Oncol Hematol 2001; 37:227–36.
    1. Kim JY, Kim ST, Nam D‐H, et al. Leukoencephalopathy and disseminated necrotizing leukoencephalopathy following intrathecal methotrexate chemotherapy and radiation therapy for central nerve system lymphoma or leukemia. J Korean Neurosurg Soc 2011; 50:304–10.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren